490 related articles for article (PubMed ID: 38794190)
1. The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.
Curcio A; Rocca R; Alcaro S; Artese A
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794190
[TBL] [Abstract][Full Text] [Related]
2. In the quest for histone deacetylase inhibitors: current trends in the application of multilayered computational methods.
Uba AI; Zengin G
Amino Acids; 2023 Dec; 55(12):1709-1726. PubMed ID: 37367966
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors.
Uba Aİ; Yelekçi K
Turk J Biol; 2017; 41(6):901-918. PubMed ID: 30814855
[TBL] [Abstract][Full Text] [Related]
4. Discussion on structure classification and regulation function of histone deacetylase and their inhibitor.
Han H; Feng X; He T; Wu Y; He T; Yue Z; Zhou W
Chem Biol Drug Des; 2024 Jan; 103(1):e14366. PubMed ID: 37776270
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment.
Elmezayen AD; Al-Obaidi A; Yelekçi K
J Mol Graph Model; 2021 Jul; 106():107937. PubMed ID: 34049193
[TBL] [Abstract][Full Text] [Related]
6. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
Ganai SA; Shanmugam K; Mahadevan V
J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
9. Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes.
Kandasamy S; Selvaraj M; Muthusamy K; Varadaraju N; Kannupal S; Sekar AK; Vilwanathan R
J Biomol Struct Dyn; 2023 Mar; 41(5):1690-1703. PubMed ID: 34994284
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
Krishna S; Kumar V; Siddiqi MI
Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
[TBL] [Abstract][Full Text] [Related]
12. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking.
Sixto-López Y; Bello M; Correa-Basurto J
J Biomol Struct Dyn; 2019 Feb; 37(3):584-610. PubMed ID: 29447615
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Kashyap K; Kakkar R
Comput Biol Med; 2020 Aug; 123():103850. PubMed ID: 32658783
[TBL] [Abstract][Full Text] [Related]
14. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
15. Current trends in development of HDAC-based chemotherapeutics.
Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
[TBL] [Abstract][Full Text] [Related]
16. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
[TBL] [Abstract][Full Text] [Related]
17. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial
Ganai SA; Abdullah E; Rashid R; Altaf M
Front Mol Neurosci; 2017; 10():357. PubMed ID: 29170627
[TBL] [Abstract][Full Text] [Related]
19. Role of HDACs in normal and malignant hematopoiesis.
Wang P; Wang Z; Liu J
Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
[TBL] [Abstract][Full Text] [Related]
20. Explorative study on isoform-selective histone deacetylase inhibitors.
Suzuki T
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):897-906. PubMed ID: 19721249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
